PDE7A and Parkinson disease: Moreover, as validation of PDE7 was also achieved by treatment of specific siRNA in hemiparkinsonian mice [7], the value of PDE7 as pharmacological target for PD was confirmed and the potential of S14 as disease-modifying treatment reinforced.